drugset
drugset / Trial / NCT01243008

Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation

NCT01243008 ↗

Phase 1/2 Completed 32 enrolled University of Zurich Appletree AG · collabIxodes GmbH · collab
RandomizedSingle-groupSingle-blindTreatment

Summary

IXODES GmbH intends to develop SHB001, an azithromycin dermal formulation in order to prevent Lyme disease at early stages of infection after tick bite.

Timeline

Start
2010-04
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 5 % Topical
Subject Azithromycin Small molecule 10 % Topical

Indications

Lyme disease